4,921 reports of this reaction
1.6% of all Xarelto reports
#20 most reported adverse reaction
HAEMATURIA is the #20 most commonly reported adverse reaction for Xarelto, manufactured by Janssen Pharmaceuticals, Inc.. There are 4,921 FDA adverse event reports linking Xarelto to HAEMATURIA. This represents approximately 1.6% of all 302,183 adverse event reports for this drug.
Patients taking Xarelto who experience haematuria should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMATURIA is a less commonly reported adverse event for Xarelto, but still significant enough to appear in the safety profile.
In addition to haematuria, the following adverse reactions have been reported for Xarelto:
The following drugs have also been linked to haematuria in FDA adverse event reports:
HAEMATURIA has been reported as an adverse event in 4,921 FDA reports for Xarelto. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMATURIA accounts for approximately 1.6% of all adverse event reports for Xarelto, making it a notable side effect.
If you experience haematuria while taking Xarelto, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.